Compounded GLP-1 Legal Status in 2025: What Patients and Prescribers Need to Know

Why Compounded GLP-1 Legal Status Changed in 2025

The legal authorization for large-scale compounded semaglutide and tirzepatide flowed from a single regulatory mechanism: the FDA drug shortage list. Under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), outsourcing facilities may compound copies of brand-name drugs only while those drugs appear on the FDA's active shortage database. Both semaglutide and tirzepatide were removed from that list, ending the primary legal basis for 503B mass production. [1]

The FDA confirmed removal of tirzepatide (Zepbound/Mounjaro) from the shortage list in December 2024 and semaglutide (Wegovy/Ozempic) in February 2025. [2] After those dates, outsourcing facilities that continued filling new compounded prescriptions for these drugs moved outside federal authorization. The agency set a phased compliance deadline: 503B facilities had until March 19, 2025 to stop compounding tirzepatide copies, and until May 22, 2025 for semaglutide copies. [3]

Patients who started on compounded versions before those deadlines were given a transition window to switch to commercially available Wegovy or Zepbound rather than facing an abrupt stop. The existence of that window matters clinically. SURMOUNT-4 (N=670) showed that patients who discontinued tirzepatide after 36 weeks regained approximately 14% of their body weight within 52 weeks of stopping, compared with continued weight loss in the maintenance group. [4] Abrupt discontinuation is not a neutral clinical event.

The FDA Shortage List: How It Works and Why It Mattered

The FDA Drug Shortages Database operates under 21 U.S.C. § 356c and related regulations. A drug enters the list when a manufacturer notifies FDA of an anticipated supply disruption, or when FDA independently identifies one. [5] Presence on the list triggers the 503B compounding exemption from the standard new-drug-approval requirement.

Both semaglutide and tirzepatide landed on the shortage list as demand from the SELECT and SURMOUNT trial results accelerated prescriptions far beyond manufacturing capacity. SELECT (N=17,604) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide 2.4 mg versus placebo over a median 34.2 months, which expanded the eligible patient population well beyond obesity alone. [6] SURMOUNT-1 (N=2,539) showed mean body weight reduction of 22.5% with tirzepatide 15 mg at 72 weeks versus 2.4% with placebo. [7] That level of efficacy generated demand the supply chain could not absorb quickly enough.

Once Novo Nordisk and Eli Lilly demonstrated adequate supply restoration to FDA's satisfaction, the drugs were delisted. Compounders challenged those decisions in federal court. As of the article's review date, FDA's removal decisions have been upheld, and the 503B pathway remains closed for standard semaglutide and tirzepatide copies.

503A vs 503B: The Core Legal Distinction

503A and 503B describe two entirely different categories of compounding pharmacy, each governed by a separate section of the FD&C Act. [8] Confusing them is the single most common error patients make when evaluating whether a pharmacy is operating legally.

503A pharmacies are state-licensed compounding pharmacies that prepare medications for individual patients based on a valid, patient-specific prescription from a licensed prescriber. They are not required to register with FDA, but they must comply with state board of pharmacy regulations and use pharmaceutical-grade ingredients. Under 503A, compounding semaglutide or tirzepatide for a specific named patient with a documented medical need can remain legal even after the shortage list removal, because 503A has never depended solely on shortage status in the same way 503B does. [9]

503B outsourcing facilities are federally registered, FDA-inspected facilities that may produce compounded drugs in bulk without patient-specific prescriptions. They can sell directly to healthcare providers and distribute across state lines. Their authority to compound copies of FDA-approved drugs is explicitly tied to shortage status. With semaglutide and tirzepatide off the shortage list, 503B facilities lost federal authorization for those specific copies. [10]

The practical difference for a patient: a prescription filled by a 503A state-licensed compounding pharmacy with documented individualized need may still be legal. A vial shipped from a 503B warehouse after May 2025 without shortage-list authorization is not. Asking your pharmacy which designation it holds is not optional at this point.

What "Salt Forms" Mean and Why the FDA Considers Them Adulterated

Several compounding pharmacies shifted to marketing semaglutide sodium or semaglutide acetate after the shortage-list removal, arguing these are chemically distinct from the brand-name semaglutide free base and therefore not covered by the same restrictions. FDA has rejected that argument explicitly. [11]

The agency's position, stated in a March 2025 guidance document, is that semaglutide sodium and semaglutide acetate are not the same active pharmaceutical ingredient as FDA-approved semaglutide, have not been evaluated for safety or efficacy in any submitted clinical trial, and produce product that is considered adulterated under 21 U.S.C. § 351. [12] No peer-reviewed pharmacokinetic data comparing semaglutide acetate to the reference standard has been published in an indexed journal as of this article's review date.

From a patient safety standpoint, this matters. STEP-1 (N=1,961) established the 14.9% mean weight loss at 68 weeks for semaglutide 2.4 mg using the specific formulation tested in Novo Nordisk's manufacturing process. [13] Substituting a different salt form means the pharmacokinetic profile, injection-site tolerability, and dose escalation schedule validated in STEP-1 and STEP-3 cannot be assumed to apply. [14] A compounding pharmacy marketing semaglutide acetate as equivalent to Wegovy is making a claim that FDA has not authorized and that existing trial data does not support.

How to Verify a Compounding Pharmacy's Legal Status

Verification takes about ten minutes and requires checking four sources. Each check answers a distinct question about legitimacy.

Step 1. Confirm 503B registration with FDA. The FDA maintains a publicly searchable list of registered 503B outsourcing facilities at fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities. [15] If a pharmacy claims to be a 503B facility and does not appear on this list, that claim is false.

Step 2. Check state board of pharmacy licensure. For 503A pharmacies, licensure is state-specific. The National Association of Boards of Pharmacy (NABP) maintains a database at nabp.pharmacy. An unlicensed online pharmacy that ships across state lines without proper registration is operating outside federal law regardless of what it claims about its compounding status. [16]

Step 3. Look up the pharmacy in FDA's warning letter database. The FDA posts all issued warning letters at fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters. A pharmacy that has received a recent GLP-1-related warning letter and is still operating warrants serious scrutiny. [17]

Step 4. Confirm your prescription is patient-specific. A legitimate 503A compound is dispensed against a prescription with your name, your prescriber's DEA or NPI number, and a diagnosis code or clinical notation. A pharmacy that offers to ship a vial without a valid prescription is violating federal law. Period.

The four-step process above represents HealthRX's internal verification framework, developed in collaboration with our pharmacy oversight team and reviewed against current FDA guidance. No published consumer guide has operationalized these four checks in sequence as a patient-facing protocol.

Compounded vs Brand-Name GLP-1: Safety Differences That Are Actually Documented

The safety comparison between compounded and brand-name GLP-1 medications is not hypothetical. FDA's adverse event reporting system (FAERS) received compounding-related GLP-1 adverse event reports beginning in 2023, and the agency issued a safety communication specifically addressing contamination and dosing error risks from compounded versions. [18]

The documented safety differences fall into three categories.

Sterility and contamination. Brand-name Wegovy and Zepbound are manufactured under Current Good Manufacturing Practice (cGMP) regulations enforced by FDA inspectors. Compounded products from 503A pharmacies are not subject to the same cGMP inspection frequency. A 2023 FDA inspection of a 503B GLP-1 compounder found particulate contamination in multiple vials. [19]

Dosing accuracy. Wegovy is supplied in a fixed-dose autoinjector pen, making subcalculation errors by patients nearly impossible. Many compounded semaglutide formulations arrive as multi-dose vials requiring patients to draw doses with an insulin syringe. Dosing errors with multi-dose vials have been reported to FAERS and represent a real-world safety signal that does not exist with the brand device. [18]

Excipient differences. The Wegovy formulation uses sodium phosphate dibasic heptahydrate, sodium phosphate monobasic monohydrate, propylene glycol, and phenol as excipients, as listed in the FDA-approved label. [20] Compounded formulations vary by pharmacy. A patient who experiences an injection-site reaction to a compounded version cannot assume that switching to Wegovy will produce the same reaction, and vice versa. The two are not pharmaceutical equivalents.

STEP-2 (N=1,210) confirmed semaglutide's glycemic efficacy in type 2 diabetes with a 1.6% HbA1c reduction at 68 weeks. [21] STEP-5 demonstrated durability: at 104 weeks, patients on semaglutide 2.4 mg maintained 15.2% mean weight loss versus 2.6% regain in the placebo group. [22] None of those outcomes can be attributed to compounded versions, because no compounded formulation has been tested in a controlled trial.

STEP-8 (N=338) compared semaglutide 2.4 mg to liraglutide 3 mg and found 15.8% versus 6.4% mean weight loss at 68 weeks. [23] The Zepbound label documents tirzepatide's dual GIP/GLP-1 receptor agonism, a mechanistic difference from semaglutide that also has no equivalent in any compounded peptide on the market. [24]

Tirzepatide-Specific Compounding: What Remains Available

Tirzepatide left the shortage list earlier than semaglutide, and its compounding situation is slightly further along in enforcement. The 503B deadline for tirzepatide was March 19, 2025. 503A patient-specific tirzepatide compounding technically remains available, but the practical access is narrower than for semaglutide because fewer 503A pharmacies maintain the equipment and API sourcing to produce tirzepatide to adequate quality standards.

SURMOUNT-2 (N=938) showed tirzepatide reduced HbA1c by 2.1 to 2.4 percentage points depending on dose in patients with type 2 diabetes and obesity at 72 weeks. [25] SURMOUNT-3 (N=806) showed that patients who received intensive lifestyle intervention first and then transitioned to tirzepatide lost an additional 18.4% of body weight over 72 weeks on top of the lifestyle-phase loss. [26] These outcomes, produced with the FDA-approved Zepbound formulation, cannot be transferred to a compounded analog.

Patients seeking tirzepatide through a compounding pharmacy after March 2025 should request written documentation of the pharmacy's 503A state license, the API source and certificate of analysis, and the prescriber's patient-specific clinical rationale. If any of those three documents are unavailable, the dispensing arrangement is not legally sound.

What Happens if You Are Already on a Compounded GLP-1

Patients currently taking a compounded GLP-1 dispensed before the respective deadline are not in legal jeopardy themselves. Federal enforcement targets manufacturers and pharmacies, not patients. The clinical question is what to do next.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Weight regain commonly occurs after stopping pharmacological treatment for obesity, and long-term medication use may be needed in many patients to maintain weight loss." [27] Stopping abruptly to wait for insurance approval of brand-name product carries the SURMOUNT-4-documented risk of 14% weight regain within 52 weeks. [4]

The most straightforward path for most patients is a conversation with the prescribing clinician about switching to Wegovy or Zepbound, submitting a prior authorization, and requesting a bridge supply or a manufacturer patient assistance program in the interim. Novo Nordisk's Wegovy savings card program and Eli Lilly's Zepbound savings card both cap out-of-pocket costs for commercially insured patients, though terms change and should be confirmed directly with each manufacturer.

The Role of Telehealth Prescribers in This Regulatory Transition

Telehealth platforms that prescribe compounded GLP-1 medications are subject to the same FD&C Act provisions as brick-and-mortar clinics. A telehealth prescriber cannot authorize a 503B facility to ship a non-shortage compounded drug any more than an in-person physician could. The prescription legality question and the pharmacy legality question are separate: a valid prescription from a licensed clinician does not make an unauthorized compounding arrangement legal.

The DEA's telemedicine prescribing rules, extended through 2025 under a temporary exemption, do allow prescribing of non-controlled substances via audio-video encounter without a prior in-person visit. [28] GLP-1 receptor agonists are not controlled substances, so telehealth prescribing of brand-name Wegovy or Zepbound is straightforwardly legal provided the prescriber is licensed in the patient's state and the clinical encounter meets standard-of-care documentation requirements.

A prescriber who claims their telehealth platform has a "special arrangement" with a 503B compounder that is exempt from the shortage-list rules is making a legally unsupportable statement. No such exemption exists in FDA guidance or federal statute.

SURMOUNT and STEP Trial Outcomes Support Brand-Name Use as the Standard

The clinical evidence base for GLP-1 receptor agonists exists entirely for brand-name formulations manufactured to the exact specifications used in registered trials. STEP-3 (N=611) combined semaglutide 2.4 mg with intensive behavioral therapy and produced 16.0% mean weight loss at 68 weeks, compared with 5.7% in the placebo-plus-behavioral-therapy group, (P<0.001). [14] The Wegovy label, updated in 2024, incorporates the full STEP program safety database covering more than 4,500 patient-years of exposure. [20]

AACE/ACE obesity guidelines, updated and indexed in PubMed, state that "anti-obesity medications should be used as part of a comprehensive lifestyle intervention program" and emphasize that evidence-based pharmacotherapy means medications with a documented trial record. [29] A compounded formulation, however well-made, does not have that record.

Patients choosing to transition to brand-name product are not losing efficacy. They are gaining the documented safety profile, the precision delivery device, and the regulatory oversight their treatment deserves.

If cost is the barrier, the brand-name patient assistance infrastructure is more developed in 2025 than at any point previously. Novo Nordisk reported that as of Q1 2025, more than 60% of commercially insured U.S. Wegovy prescriptions had copay assistance applied, though that figure should be confirmed through the prescriber's office given quarterly program changes.